title: Clinical usefulness of transcription-mediated amplification and hybridization protection assay in imatinib-treated chronic myelogenous leukemia patients.
authors.forename: M
authors.initials: M
authors.lastname: Sumi
authors.forename: T
authors.initials: T
authors.lastname: Tauchi
authors.forename: G
authors.initials: G
authors.lastname: Sashida
authors.forename: N
authors.initials: N
authors.lastname: Shoji
authors.forename: A
authors.initials: A
authors.lastname: Gotoh
authors.forename: Y
authors.initials: Y
authors.lastname: Itoh
authors.forename: K
authors.initials: K
authors.lastname: Miyazawa
authors.forename: Y
authors.initials: Y
authors.lastname: Kimura
authors.forename: J H
authors.initials: JH
authors.lastname: Ohyashiki
authors.forename: K
authors.initials: K
authors.lastname: Ohyashiki
mesh_terms: D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis*; D018365:Neoplasm, Residual / Q000175:diagnosis; D021141:Nucleic Acid Amplification Techniques; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D012334:RNA, Neoplasm / Q000032:analysis*
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D012334:RNA, Neoplasm; D000068877:Imatinib Mesylate